重组人内皮抑素结合化疗对晚期非小细胞肺癌患者血清LMTK-3、IGFBP-7的影响  

Effect of recombinant human endostatin plus chemotherapy on serum LMTK-3 and IGFBP-7 in patients with advanced non-small cell lung cancer

作　　者：韩敏 王坚 王久胜 Min Han;Jian Wang;Jiu-sheng Wang(Department of Radiation Oncology,Manan City People’s Hospital,Manan,Anhui 243000,China)

机构地区：[1]安徽省马鞍山市人民医院肿瘤科放疗病区,安徽马鞍山243000

出　　处：《中国现代医学杂志》2018年第9期55-59,共5页China Journal of Modern Medicine

摘　　要：目的探讨重组人内皮抑素结合化疗对晚期非小细胞肺癌患者血清Lemur酪氨酸激酶3(LMTK-3)、胰岛素样生长因子结合蛋白7(IGFBP-7)的影响。方法选取2012年1月-2015年1月于该院收治的NSCLC患者86例为研究对象,按随机数字表法分为观察组和对照组,每组43例。对照组患者采取吉西他滨+顺铂化疗。观察组在对照组基础上联合恩度治疗。对两组患者的临床疗效、不良反应、外周血血管内皮生长因子(VEGF)、胰岛素样生长因子1(IGF-1)、LMTK-3、IGFBP表达水平进行评价。结果观察组治疗客观有效率、总有效率高于对照组(P<0.05),观察组的疗效优于对照组,差异有统计学意义(P<0.05)。两组患者的不良反应发生率并差异无统计学意义(P>0.05)。两组患者治疗后VEGF、IGF-1及LMTK-3水平较治疗前更低,GFBP水平较治疗后更高,差异有统计学意义(P<0.05),且观察组治疗后VEGF、IGF-1及LMTK-3水平较对照组更低,IGFBP-7更高,差异有统计学意义(P<0.05)。结论重组人内皮抑素联合化疗可有效降低NSCLC患者的血清LMTK3水平,升高血清IGFBO-7水平,患者的疗效良好,不良反应较低。Objective To investigate the effect of recombinant human endostatin combined with chemotherapy on serum LMTK-3 and IGFBP-7 in patients with advanced non-small cell lung cancer.Methods Totally 86 cases of patients diagnosed with advanced non-small cell lung cancer in our hospital from January 2012 to January 2015 were involved in this study.Patients were randomly divided into observation group and control group(n=43).Patients from control group received gemcitabine+cisplatin chemotherapy.Patients from observation group received endostar in addition to standard treatment.The therapeutic efficacy,side effects and concentration of VEGF,IGF-1,LMTK-3 and IGFBP were recorded.Results The therapeutic efficacy in observation group was significantly higher than that of the control group(χ2=5.403,7.493,P<0.05).No statistically significant difference in the incidence of adverse events between the two groups was observed.The levels of VEGF,IGF-1 and LMTK-3 in both groups were significantly increased while GFBP decreased post treatments when compared with that prior to treatments(P<0.05).Concentrations of VEGF,IGF-1 and LMTK-3 in observation group were downregulated while IGFBP-7 upregulated significantly when compared with control group(P<0.05).Conclusion Recombinant human endostatin combined with chemotherapy is a promising option for treatment of NSCLC patients with good efficacy and less adverse reactions.

关 键 词：重组人内皮抑素 化疗 晚期非小细胞肺癌 Lemur酪氨酸激酶3 胰岛素样生长因子结合蛋白-7 

分 类 号：R734.2[医药卫生—肿瘤]